Proteomic Biomarkers In Drug Development

Biomarker (noun): Biomarkers are cellular, biochemical, or molecular alterations that are measurable in biological media such as human tissues, cells, or fluids. They indicate the presence of biological events or concerted events that are directly associated with a particular disease state.

Molecular Biomarkers (noun): Molecular biomarkers include proteins, carbohydrates, nucleic acids, and other compounds that provide insight into an individual’s health for screening risk factors, diagnosis, and prognosis. Molecular biomarkers are also extremely useful for drug discovery purposes.

Clinical Needs, Patient Perspective:
Am I at risk for cancer?
Is there anything I can do to alter the risk?
Do I have cancer?
Will my cancer respond to therapy?
Is my cancer responding to therapy?

Clinical Needs, Physician Perspective:
Identification of fingerprints associated with:

Prognosis at the time of diagnosis

Tumor responsiveness to therapy

Inter- and intratumor heterogeneity

Metastatic potential

Disease progression

CONTINUED: See Full PDF Document: Proteomic Biomarkers In Drug Development


Conclusions:
The study demonstrated efficacy of IND#70190 with overall improved performance scores and alleviation of asthma symptoms

Novel protein biomarkers for asthma and drug efficacy were identified

Drug effects are consistent with potent anti-inflammatory activity of IND#70190

Further clinical development and investigation of drug mechanism of action is warranted